Oramed Pharmaceuticals Launches Phase 1A Trials Of Its Insulin Suppository

Oramed Pharmaceuticals Launches Phase 1A Trials Of Its Insulin Suppository
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, announced today that it has received approval from the South Africa Medicines Control Council (MCC) to begin conducting Phase 1A trials on eight healthy human volunteers for ORMD 0802, the company's newly developed insulin suppository.

Oramed Pharmaceuticals Launches Phase 1A Trials Of Its Insulin Suppository
An Insulin Suppository Represents an Important Development in the Treatment of Diabetes as it Provides a Painless Alternative for Effective Insulin Delivery Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; http://www.oramed.

Novexel Reports Positive Phase II Trial Results With NXL103 In Adult Patients With Community Acquired Pneumonia
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP).

Cold Virus Found To Manipulate Genes
Sneezing, runny nose and chills? You might blame the human rhinovirus (HRV), which causes 30 to 50 percent of common colds. But in reality, it's not the virus itself but HRV's ability to manipulate your genes that is the true cause of some of the most annoying cold symptoms. For the first time, researchers have shown that HRV hijacks many of your genes and causes an overblown immune response that ends up with your nose being overblown.